| scholarly article | Q13442814 |
| P50 | author | Mariusz Ratajczak | Q11770192 |
| Tomasz Jadczyk | Q57618158 | ||
| Jan E Zejda | Q59215607 | ||
| Magdalena Kucia | Q61942769 | ||
| Barbara Dołęgowska | Q61942784 | ||
| Wojciech Wojakowski | Q48860870 | ||
| Kamil Barański | Q88053515 | ||
| Marcin Syzdół | Q89296628 | ||
| Edyta Nabialek-Janusz | Q90989891 | ||
| Radosław Kurzelowski | Q90989894 | ||
| Wojciech Wanha | Q92138286 | ||
| Niewczas Marta | Q92646784 | ||
| P2860 | cites work | Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate | Q22010773 |
| Trafficking and Functions of Bioactive Sphingolipids: Lessons from Cells and Model Membranes | Q26771645 | ||
| Principles of bioactive lipid signalling: lessons from sphingolipids | Q28265743 | ||
| Endothelial cell activation by pore-forming structures: pivotal role for interleukin-1alpha | Q28376983 | ||
| Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium | Q28568260 | ||
| Sterile inflammation: sensing and reacting to damage | Q29620014 | ||
| Sphingosine-1-phosphate receptor subtypes differentially regulate smooth muscle cell phenotype | Q30440617 | ||
| Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor | Q33266079 | ||
| Cardiac effects of amiselimod compared with fingolimod and placebo: results of a randomised, parallel-group, phase I study in healthy subjects | Q33593619 | ||
| Activation and control of complement, inflammation, and infection associated with the use of biomedical polymers | Q34100748 | ||
| Novel evidence that crosstalk between the complement, coagulation and fibrinolysis proteolytic cascades is involved in mobilization of hematopoietic stem/progenitor cells (HSPCs) | Q34253089 | ||
| Heparin-coated cardiopulmonary bypass circuits: current status | Q34375503 | ||
| Adherence of neutrophils to cultured human microvascular endothelial cells. Stimulation by chemotactic peptides and lipid mediators and dependence upon the Mac-1, LFA-1, p150,95 glycoprotein family | Q34566898 | ||
| Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. | Q34748080 | ||
| Coordinated proteomic signature changes in immune response and complement proteins in acute myocardial infarction: the implication of serum amyloid P-component | Q34977215 | ||
| Molecular intercommunication between the complement and coagulation systems | Q35067949 | ||
| The relationship between rheumatoid factor levels and coronary artery lesion complexity and severity in patients with stable coronary artery disease | Q35214498 | ||
| Complement component 3 is necessary to preserve myocardium and myocardial function in chronic myocardial infarction | Q35386562 | ||
| A novel view of the adult bone marrow stem cell hierarchy and stem cell trafficking. | Q35407728 | ||
| The inflammatory response in myocardial injury, repair, and remodelling. | Q35529656 | ||
| Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit? | Q35845114 | ||
| Complement activation and cardiac surgery: a novel target for improving outcomes | Q36269099 | ||
| Systemic inflammatory response to coronary artery bypass graft surgery | Q36287567 | ||
| Complement in Action: An Analysis of Patent Trends from 1976 Through 2011. | Q36503765 | ||
| Complement mediators in ischemia-reperfusion injury | Q36548838 | ||
| Alternative complement pathway activation during invasive coronary procedures in acute myocardial infarction and stable angina pectoris. | Q52840282 | ||
| Dose-dependent effect of aspirin on the level of sphingolipids in human blood. | Q53087596 | ||
| Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. | Q53374301 | ||
| The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. | Q54568085 | ||
| Novel evidence for enhanced stem cell trafficking in antipsychotic-naïve subjects during their first psychotic episode. | Q54579563 | ||
| Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes | Q57952121 | ||
| Generation of C5a in the absence of C3: a new complement activation pathway | Q58523865 | ||
| Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction | Q36853117 | ||
| Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury | Q36923715 | ||
| Sphingolipid therapy in myocardial ischemia-reperfusion injury | Q36967504 | ||
| Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia | Q37099437 | ||
| Sphingosine-1-phosphate in the regulation of vascular tone: a finely tuned integration system of S1P sources, receptors, and vascular responsiveness | Q37231441 | ||
| Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice. | Q37241418 | ||
| Sphingosine-1-phosphate receptor signalling in the heart | Q37413862 | ||
| Role of complement and perspectives for intervention in ischemia-reperfusion damage. | Q37831329 | ||
| An emerging link in stem cell mobilization between activation of the complement cascade and the chemotactic gradient of sphingosine-1-phosphate | Q38043743 | ||
| Identification of inflammatory mediators and their modulation by strategies for the management of the systemic inflammatory response during cardiac surgery | Q38070454 | ||
| Processes of sterile inflammation. | Q38135408 | ||
| Sphingosine-1-phosphate as a potential target for the treatment of myocardial infarction | Q38196279 | ||
| Platelets and the complement cascade in atherosclerosis | Q38382518 | ||
| Immune cells in repair of the infarcted myocardium | Q38932028 | ||
| Activation of the complement system at the interface between blood and artificial surfaces | Q39633041 | ||
| Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage | Q40152525 | ||
| S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate | Q40405662 | ||
| Quantification of sphingosine 1-phosphate by validated LC-MS/MS method revealing strong correlation with apolipoprotein M in plasma but not in serum due to platelet activation during blood coagulation | Q40531538 | ||
| An active form of sphingosine kinase-1 is released in the extracellular medium as component of membrane vesicles shed by two human tumor cell lines. | Q40729905 | ||
| Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium | Q41451198 | ||
| Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient | Q42026885 | ||
| The membrane attack complex of complement induces interleukin-8 and monocyte chemoattractant protein-1 secretion from human umbilical vein endothelial cells | Q42804319 | ||
| Sphingosine-1-phosphate: a platelet-activating sphingolipid released from agonist-stimulated human platelets | Q42826228 | ||
| Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. | Q43282758 | ||
| Cardiovascular disease in Europe 2014: epidemiological update | Q43434768 | ||
| Sphingosine-1-phosphate effects on guinea pig atrial myocytes: Alterations in action potentials and K+ currents | Q46376442 | ||
| Lipid metabolism: sources and stability of plasma sphingosine-1-phosphate | Q46391633 | ||
| Decreased phosphatidylcholine plasmalogens--A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction | Q46610151 | ||
| C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction | Q47191457 | ||
| Complement as a regulator of adaptive immunity | Q47196269 | ||
| A spectrophotometric method for quantitating hemoglobin in plasma or serum | Q47972788 | ||
| [Overview of methods used for determination of selected sphingolipids in different biological materials] | Q61943547 | ||
| Protamine inhibits plasma carboxypeptidase N, the inactivator of anaphylatoxins and kinins | Q69941019 | ||
| C5a-dependent up-regulation in vivo of lung vascular P-selectin | Q73064427 | ||
| Shooting the messenger: oxidative stress regulates sphingosine-1-phosphate | Q79494355 | ||
| Serum C-reactive protein and complement proteins in patients with acute myocardial infarction | Q81377299 | ||
| The complement system is activated in a biphasic pattern after coronary artery bypass grafting | Q82978125 | ||
| Corrigendum to: cardiovascular disease in Europe 2014: epidemiological update | Q86306967 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sphingolipids | Q410395 |
| coronary artery disease | Q844935 | ||
| P304 | page(s) | 2691934 | |
| P577 | publication date | 2018-07-09 | |
| P1433 | published in | Mediators of Inflammation | Q2144494 |
| P1476 | title | Bioactive Sphingolipids, Complement Cascade, and Free Hemoglobin Levels in Stable Coronary Artery Disease and Acute Myocardial Infarction | |
| P478 | volume | 2018 |
| Q90219783 | Lipid mediators of insulin signaling in diabetic kidney disease | cites work | P2860 |
Search more.